Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2012

View Archived Issues

Kyowa Hakko Kirin reviews accomplishments of 2011

RNA-loaded dendritic cell vaccine shows promise combined with sunitinib

EpiCept seeks fast track designation for AmiKet

African sleeping sickness drug shows potential to treat leishmaniasis

Foretinib shows promise in large papillary renal cell carcinoma study

New vaccines for human papillomavirus prepared in China

Artificial Cell Technologies patents novel RSV vaccines

New phase I safety data presented on stroke therapy

Scientists at Calmune prepare novel antibodies for RSV infection

Bradykinin B1 receptor antagonist reduces pain in vivo

Vertex Pharmaceuticals claims novel HCV NS5B inhibitors

Rib-X Pharmaceuticals receives milestone payment under RX-04 collaboration

Amicus receives grant for Pompe's disease program

Japanese authorities remove condition for approval of Tarceva in NSCLC

Merck & Co. recaps milestones of fourth quarter and full year 2011

Erivedge launched in U.S.

Alexion Pharmaceuticals completes acquisition

FDA sets date for crofelemer NDA

Phase II study of ziprasidone commences in Japan

Line extension for Vyvanse in U.S.

Omeros provides update on phase III OMS-302 trial

Bio-Path completes treatment of second cohort in BP-100-1.01 study

Health Canada approves ipilimumab

FDA grants priority review for pertuzumab

Orion plans new studies of inhalable budesonide/formoterol combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...